Search
Showing results for "Childhood interstitial lung disease "
Lung function trajectories are impaired in survivors of very preterm birth
A The Kids Research Institute Australia study published in The Lancet Child & Adolescent Health has found that survivors of very preterm birth face declining lung function
This chapter deals with asbestos-related non-malignant pleural disease and mesothelioma.
There is a growing understanding that chronic respiratory diseases in adults have their origins in early life
Structural and functional defects within the lungs of children with cystic fibrosis (CF) are detectable soon after birth and progress throughout preschool years often without overt clinical signs or symptoms. By school age, most children have structural changes such as bronchiectasis or gas trapping/hypoperfusion and lung function abnormalities that persist into later life. Despite improved survival, gains in forced expiratory volume in one second (FEV1) achieved across successive birth cohorts during childhood have plateaued, and rates of FEV1 decline in adolescence and adulthood have not slowed. This suggests that interventions aimed at preventing lung disease should be targeted to mild disease and commence in early life.
The cumulative effect of inflammation and infection on structural lung disease in early cystic fibrosis Lung inflammation and infection are common
Identifying pediatric lung disease: A comparison of forced oscillation technique outcomes Abstract Rationale Increasing evidence suggests the forced
This review aims to summarise what is known about the long-term pulmonary outcomes of contemporary preterm birth
Our data associates IL-1α with early structural lung damage in CF and suggests this pathway as a novel anti-inflammatory target
Newly developed quantitative chest computed tomography (CT) outcomes designed specifically to assess structural abnormalities related to cystic fibrosis (CF) lung disease are now available. CFTR modulators potentially can reduce some structural lung abnormalities. We aimed to investigate the effect of CFTR modulators on structural lung disease progression using different quantitative CT analysis methods specific for people with CF (PwCF).